Cell Therapy News

CHICAGO — A novel T-cell receptor therapy showed promising antitumor activity in patients with advanced soft tissue sarcoma, according to results from a phase 1 study presented at ASCO Annual Meeting.

CHICAGO — A single infusion of letetresgene autoleucel demonstrated antitumor activity among patients with advanced or metastatic myxoid/round cell liposarcoma, results from a pilot study suggested.

CHICAGO — Axicabtagene ciloleucel exhibited comparable efficacy and safety for large B-cell lymphoma regardless of patients’ race or ethnicity, according to study results presented at ASCO Annual Meeting.

A woman with metastatic pancreatic cancer attained a 72% partial response with T-cell receptor gene therapy, according to a report published in The New England Journal of Medicine.

Multiple myeloma is the most common indication for autologous stem cell transplantation worldwide.

The FDA granted accelerated approval to tisagenlecleucel for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Although chimeric antigen receptor T-cell therapy is approved for treatment of multiple myeloma, commercially available products are limited to patients who received at least four prior lines of therapy.

First-line therapy with axicabtagene ciloleucel induced objective responses in 89% of patients with high-risk large B-cell lymphoma, according to phase 2 study results.

One of the major complaints of clinicians who treat patients with chimeric antigen receptor T-cell therapies is the time required to produce the highly individualized treatment.

Black and Hispanic patients who received chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma achieved similar efficacy outcomes as white and Asian individuals, according to study results.